Real-World Incidence of Lung Malignancy and Chronic Obstructive Pulmonary Disease with Inhaled Insulin in People with Diabetes
Main finding · Any lung cancerResult — go to the resultRelative risk 1 95% CI 0.42–2.40Authors' conclusion
No association was found between inhaled insulin and any lung malignancy. Inhaled insulin was associated with a threefold increase in COPD versus RAA although the absolute risk was low. The biological plausibility of this association is not definitive. Given the retrospective design and potential for ascertainment bias, causal inference is limited although findings underscore the need for continued evaluation of inhaled insulin's pulmonary safety.
Study context
- Population
- Adults with T1D or T2D prescribed inhaled insulin or rapid-acting analogue (RAA) insulin, TriNetX Networkpropensity score matched
- Exposure
- Inhaled insulin vs rapid-acting analogue insulin
- Outcome
- Risk of lung malignancy and chronic obstructive pulmonary disease (COPD)
Methodological detailspropensity score matched, TriNetX Network
- Propensity score matched
- TriNetX Network
Main finding
Any lung cancer
Relative risk
1
95% CI 0.42–2.40
P = 0.999
Events by group
Inhaled insulin
≤ 10/2530
events
RAA insulin
≤ 10/2531
events
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Inhaled insulin | RAA insulin | RR (95% CI) | P value | |
|---|---|---|---|---|---|
| Composite COPD outcomeGreater risk with inhaled insulin · after propensity score matching | 1.6% | 0.5% | 3.45 (1.82–6.54) | P < 0.001 | |
| 0.10.31310Relative risk (log scale) |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →